吉非替尼与含铂方案治疗晚期非小细胞肺癌的对照分析  

Gefitinib and cisplatin in the treatment of advanced non-small cell lung cancer: a comparative analysis

作　　者：王开云[1] 徐城林[1] 周云萍[1] 张鑫[1] 田智萍[1] 熊婧[1] 

机构地区：[1]四川攀枝花市第二人民医院,四川攀枝花617068

出　　处：《中国民族民间医药》2012年第15期29-30,共2页Chinese Journal of Ethnomedicine and Ethnopharmacy

摘　　要：目的:对照分析吉非替尼与含铂方案治疗晚期非小细胞肺癌的临床疗效及不良反应、社会效益。方法:随机选择40例晚期非小细胞肺癌内科初治患者,非随机分为甲乙两组各20例,甲组给予吉非替尼250 mg口服1次/天治疗;乙组给予含铂方案TP(紫杉醇+顺铂)治疗,一个月后评价疗效,病情进展则停止治疗,并详细记录不良反应。结果:甲组:20例中症状完全或明显缓解16例,多在用药1周后见效,临床受益率为80.0%(16/20)。腺癌16例,CR2例,PR8例,SD5例,PD1例,有效率(CR PR)为62.5%(10/16);鳞癌4例,SD2例,PD2例。总有效率为50.0%(10/20)。中位无进展时间为9个月,一年生存为45.0%(9/20)。不良反应,主要为痤疮样皮疹、恶心及腹泻。治疗检查费用:人均约2500元/月。乙组:20例中症状完全或明显缓解15例,多在用药2周后见效,临床受益率为75.0%(15/20)。腺癌16例,CR2例,PR7例,SD6例,PD1例,有效率(CR PR)为56.3%(9/16);鳞癌4例,SD2例,PD2例。总有效率为45.0%(9/20)。中位无进展时间为8个月,一年生存为40.0%(8/20)。不良反应,主要为恶心呕吐、食欲下降及脱发。治疗检查费用:人均约5500元/月。结论:吉非替尼治疗中晚期非小细胞肺癌,尤其是肺腺癌疗效确切,毒性反应较含铂方案轻,医疗费用较低,社会效益明显,值得临床一线推荐治疗晚期肺腺癌。Purpose - control analysis of efficacy of non - erlotinib and Platinum containing regimens in advanced non - small cell lung cancer ： a clinical efficacy and side effects, social benefit. Method of random selection of 40 cases with advanced non - small cell lung cancer patients with newly diagnosed medical, non - randomly divided into two groups of 20 cases, gefitinib group a given 250 mg orally 1 time/day treatment; b containing cisplatin TP （Taxol ＋ cisplatin） treatment, one month after the evaluation of efficacy, dis- ease progress to stop treatment and detailed record of adverse reactions. Results of Group ： 20 cases symptoms completely or significant- ly ease in 16 cases, 1 week after the results of drug use, clinical benefit rate （80%）. Adenocarcinoma in 16 cases, CR2, PR8 exam- ple, SDS, PD1, efficiency （CR PR） （62. 5% ）, 4 cases of squamous cell carcinoma, SD2, PD2 cases. Total effective rate （50%）. No progress in time for 9 months, one year survival （45%）. Adverse events, mainly for acne -like skin rash, nausea and diarrhoea. Treatment expenses ： per capita of about $ 2, 500 per month. Group b ： 20 cases symptoms completely or significantly ease in 15 ca- ses, medication after 2 weeks of work, clinical benefit rate （75%）. Adenocarcinoma in 16 cases, CR2, PR7, SD6, PD1, efficiency （ CR PR） （56. 3% ）, 4 cases of squamous cell carcinoma, SD2, PD2 cases. Total effective rate （45%）. No progress in time of 8 months, one year survival （40%）. Adverse reactions, mainly nausea, vomiting, appetite and hair loss. Treatment expenses： about $ 5, 500 per person per month. Conclusion of gefitinib in the treatment of advanced non - small cell lung cancer, particularly lung canc- er compared with cisplatin in good efficacy, toxicity is light, lower medical expenses, social benefits clearly, it is worth recommending.

关 键 词：吉非替尼 含铂方案 晚期非小细胞肺癌 临床疗效 社会效益 

分 类 号：R730.55[医药卫生—肿瘤]